Browsing by Author "Edogbanya, H. O."

Now showing 1 - 2 of 2
  • Item
    Mathematical analysis of a staged progression HIV/AIDS model with screening and drug resistance
    (ABACUS. 43(2) 162 – 179. Published by the Mathematical Association of Nigeria, 2016) Akinyemi, S. T; Ibrahim, M. O.; Moses, M. A.; Edogbanya, H. O.; Odetunde, O.
    In this paper, a staged progression model for HIV/AIDS transmission dynamics in the presence of screening and drug resistance is developed and rigorously analyzed. The model consist of eight mutually exclusive subpupolations with two equilibria, namely the disease free and endemic equilibrium. The disease free equilibrium is shown to be globally asymptotically stable whenever the effective reproduction number is less than unity by constructing Lyapunov function. Using the Kranoselski sublinearity trick and Lyapunov function, the endemic equilibrium for a special case was establish to be locally and globally asymptotically stable respectively when its associated effective reproduction number exceeds unity
  • Item
    Mathematical modeling of Hepatitis B transition to primary liver cancer with consideration of partial immunity.
    (Journal of the Nigerian Association of Mathematical Physics 32 211 – 220. Published by the Nigerian Association of Mathematical Physics., 2015) Odetunde, O.; Ibrahim, M. O.; Lawal, J.; Edogbanya, H. O.; Akinyemi, S. T
    This work study the rate of progression of Hepatitis B to Primary Liver Cancer, the effect of therapeutic treatment on the HBV and the role of vaccination of pregnant women as passive immunity for the unborn child. The equilibria states of both the disease free and the endemic were calculated. Positivity of the solution of the model was analyzed and the effective reproduction number was computed. The analysis of the reproduction number at the DFE indicated a substantial decrease in the number of secondary infection rate as a result of passively acquired immunity of the infant and the therapeutic treatment now available to HBV. However, the study show that the rate of progression to primary liver cancer (PLC) will be on the increase if the treatment is not affordable to all HBV patients